Pharmacoeconomical evaluation of hypertension with diabetes mellitus in a teaching hospital in urban Bangalore


  • Rajat Rana Department of Pharmacy Practice, Gautham College of Pharmacy, Bangalore 560107, India
  • Alekhya Modupalli Department of Pharmacy Practice, Acharya & B. M Reddy College of Pharmacy, Bangalore 560107, India
  • Aneena Suresh Department of Pharmacy Practice, Gautham College of Pharmacy, Bangalore 560107, India
  • Mamidi Santosh Department of Pharmacology, Gautham College of Pharmacy, Bangalore 560032, India
  • Anusha B. Department of Pharmacy Practice, Gautham College of Pharmacy, Bangalore 560107, India,
  • Sourav Trivedi Department of Pharmaceutics, Gautham College of Pharmacy, Bangalore 560032, India



Pharmacoeconomics, Medication, Cost, Hospital


Background: This study was conducted to evaluate Pharmacoeconomics involved in Hypertension with Type II Diabetes in a tertiary care teaching hospital in urban Bangalore.

Methods: The study was conducted among the patients admitted to Inpatient ward of Dr B.R Ambedkar Hospital diagnosed with Type II Diabetes with Hypertension. The data was collected using prevalidated questionnaires which were specially focused on Direct Cost, Indirect Cost & Intangible Cost. The data was analyzed using SPSS version 20.

Results: The overall mean number of hospitalization days was 5.86 ± 0.39. Mean Medication Cost was recorded as Rs 2752 ± 219.7. This study also observed that mean laboratory investigation cost were 447.6 ± 19.66., Travel expenses Rs 584±163.9, Food cost was Rs 324.8 ± 26.90 & lost wages were 1402 ± 150.5. The correlation coefficient was highest between food cost and traveling expenses as 0.88 whereas least between lab investigation and lost wages as 0.001. Thyroid profile test was the costliest test prescribed overall.

Conclusions: This study concludes that the there is a huge economic burden on the patient from the lower income group. Medication cost and diagnostic cost are among the major factors that accounts for the total health care cost.


Ettaro L, Ping Z, Michael M. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics. 2004;22(3):149-64.

Angus C, Walter T, Zwirble L, Lidicker J, Clermont G, Carcillo J. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical care medicine. 2001;29(7):1303-310.

Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das A, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia. 2001;44(9):1094-101.

GuariguataL, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes research and clinical practice. 2014;103(2):137-49.

American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes care. 2013;36(4):1033-046.

Ajay S, Prabhakaran D, Jeemon P, Thankappan K, Mohan V, Ramakrishnan L, et al. Prevalence and determinants of diabetes mellitus in the Indian industrial population. Diabetic Medicine. 2008;25(10): 1187-194.

Anderson, Gerard F, Poullier J. Health spending, access, and outcomes: trends in industrialized countries. Health Affairs.1999;18(3):178-92.

Barber, Alistair J. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2003;27(2):283-90.

Chobanian V, Bakris G, Black H, William C. Cushman A, L Green et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama. 2003;289(19):2560-71.

Alberto B, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bulletin of the World Health Organization. 2003;81(1):19-27.

Marian G, Gasparello B, Ferraro J, Sharma A, Strowe R, Bendek A Integrated system including medication delivery pen, blood monitoring device, and lancer. U. S. Patent 6,192,891, issued February 27, 2001.

UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ: British Medical Journal. 1998;317(7160):720.

Alonso J, Garcia M, Laborda M, Hermoso A, Lopez F. Analysis of pharmacologic costs in the treatment of arterial hypertension. Approximation to a cost-effectiveness study. Aten Primaria. 1998;21:607-12.

Bhattacharyya K, Else B (1999). Medical costs of managed care in patients with type 2 diabetes mellitus. ClinTher. 1999;21(12):2131-42.

Borrell M, Ramon J. Pharmaceutical price regulation. Pharmacoeconomics.1991:15(3):291-03.

Nichols A, Vupputuri S, Lau H. Medical care costs associated with progression of diabetic nephropathy. Diabetes Care. 2011;34(11):2374-8.

Ramachandran A. Socio-economic burden of diabetes in India. Journal Association of Physicians of India. 2007;55:9.




How to Cite

Rana, R., Modupalli, A., Suresh, A., Santosh, M., B., A., & Trivedi, S. (2016). Pharmacoeconomical evaluation of hypertension with diabetes mellitus in a teaching hospital in urban Bangalore. International Journal of Basic & Clinical Pharmacology, 5(2), 473–477.



Original Research Articles